Ad
related to: new antipsychotic approved prescription products released
Search results
Results from the WOW.Com Content Network
In September 2024, it was approved for medical use in the United States. [ 1 ] [ 2 ] It is the first antipsychotic drug approved by the US Food and Drug Administration (FDA) to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors , which has long been the standard of care.
Antipsychotics by class Generic name Brand names Chemical class ATC code Typical antipsychotics; Acepromazine: Atravet, Acezine: phenothiazine: N05AA04
Intuniv - an extended release, non-stimulant alpha-2 adrenergic agonist used to treat attention deficit hyperactivity disorder. Available in instant-release under the brand-name Tenex. Invega (paliperidone) – atypical antipsychotic used to treat schizophrenia and schizoaffective disorder
RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 ...
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate). [2] It is developed by Intra-Cellular Therapies, licensed from Bristol ...
The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe acute pain. The drug, called Journavx ...
A few facts for you according to the folks from The Anxiety and Depression Association of America and the National Institute of Mental Health: In 2020, an estimated 14.8 million U.S. adults aged ...
Unlike other antipsychotics, pimavanserin is not a dopamine receptor antagonist, [5] but rather is a selective antagonist or inverse agonist of the serotonin 5-HT 2A receptor and to a lesser extent of the serotonin 5-HT 2C receptor. [3] Pimavanserin was first approved for medical use in 2016. [3] It was approved as a generic medication in 2024. [6]
Ad
related to: new antipsychotic approved prescription products released